BVS vs ZVRA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BVS shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Concerns include weak profitability or high valuation.
ZVRA presents a contradictory profile characterized by a weak Piotroski F-Score of 2/9, indicating poor fundamental health trends, contrasted with explosive revenue growth of 183.40%. While the current price of $10.11 is slightly above the Graham Number ($9.09) and Intrinsic Value ($9.45), the low P/E of 7.49 suggests a valuation disconnect. The company is transitioning from a history of heavy losses to sporadic profitability, but the negative ROA and low F-Score signal significant underlying financial instability. The outlook is balanced between high-growth biotech potential and poor deterministic health metrics.
Compare Another Pair
Related Comparisons
BVS vs ZVRA: Head-to-Head Comparison
This page compares Bioventus Inc. (BVS) and Zevra Therapeutics, Inc. (ZVRA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.